Acelyrin Biopharma Aims For A $1.5 billion Valuation In Its US IPO

Acelyrin Inc, a late-stage clinical biopharma company, announced on Monday that it intends to seek a valuationAcelyrin Inc, a late-stage clinical biopharma company, announced on Monday that it intends to seek a valuation of up to $1.5 billion in its initial public offering in the United States, which comes at a time when new listings are testing investors' appetite. According to a filing, the Los Angeles-based company hopes to raise up to $370 million by selling 20.6 million shares at nearly the top of its proposed price range of $16 to $18 per share.

There are signs that the IPO market is thawing. Johnson & Johnson Inc is preparing to list its consumer health business Kenvue Inc on the New York Stock Exchange this Friday, with the goal of raising $3.5 billion. SoftBank's ARM Ltd filed a confidential application with regulators for a US stock market listing last week, paving the way for the year's largest IPO offering. According to Dealogic, U.S. IPOs, excluding listings for special purpose acquisition companies, are down about 22% year to date to a total of just $2.35 billion, as stock market volatility and economic uncertainty have put many IPO hopefuls off.

Following the completion of offering, Acelyrin will be listed on the Nasdaq with its shares trading under the ticker symbol "SLRN". Morgan Stanley, Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. of up to $1.5 billion in its initial public offering in the United States, which comes at a time when new listings are testing investors' appetite. According to a filing, the Los Angeles-based company hopes to raise up to $370 million by selling 20.6 million shares at nearly the top of its proposed price range of $16 to $18 per share. There are signs that the IPO market is thawing.

Johnson & Johnson Inc is preparing to list its consumer health business Kenvue Inc on the New York Stock Exchange this Friday, with the goal of raising $3.5 billion. SoftBank's ARM Ltd filed a confidential application with regulators for a US stock market listing last week, paving the way for the year's largest IPO offering. According to Dealogic, U.S. IPOs, excluding listings for special purpose acquisition companies, are down about 22% year to date to a total of just $2.35 billion, as stock market volatility and economic uncertainty have put many IPO hopefuls off. Following the completion of offering, Acelyrin will be listed on the Nasdaq with its shares trading under the ticker symbol "SLRN". Morgan Stanley, Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering.